The Global Advanced Therapy Medicinal Products CDMO Market is projected to increase from USD 5.23 Billion in 2025 to USD 9.06 Billion by 2031, reflecting a compound annual growth rate of 9.59%. These Contract Development and Manufacturing Organizations offer specialized outsourcing services dedicated to the development and production of gene therapies, somatic cell therapies, and tissue-engineered products. This market growth is primarily driven by the rising need for biopharmaceutical companies to utilize specialized technical expertise without incurring the massive capital costs associated with internal manufacturing facilities. Furthermore, the increasing complexity of these therapeutic modalities encourages innovators to rely on the regulatory experience and established infrastructure of external partners to expedite clinical timelines and commercialization efforts.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 5.23 Billion
Market Size 2031	USD 9.06 Billion
CAGR 2026-2031	9.59%
Fastest Growing Segment	Oncology
Largest Market	North America

However, the sector faces a substantial challenge due to the scarcity of available manufacturing slots and a shortage of highly skilled personnel, which limits the capacity of service providers to effectively handle the surging volume of projects. According to the Alliance for Regenerative Medicine, the sector displayed robust activity in 2025, with a 6 percent rise in the number of global developers and a 3 percent increase in clinical trials. This expansion of the development pipeline intensifies the pressure on existing manufacturing resources, underscoring the critical necessity for significant capacity expansion within the industry.

Market Driver

The rapid expansion of cell and gene therapy clinical development pipelines serves as a primary catalyst for the Global Advanced Therapy Medicinal Products CDMO Market. As developers aggressively broaden their research initiatives, the immense volume of therapeutic candidates entering pre-clinical and clinical stages demands external manufacturing support to manage throughput. This demand is further amplified by strong sector financing, which supports the progression of these candidates through expensive development phases; for instance, the Alliance for Regenerative Medicine reported in October 2024 that the sector attracted USD 10.9 billion in investment during the first half of the year. Consequently, the industry depends heavily on contract partners, a reliance underscored by Citeline and the American Society of Gene & Cell Therapy's April 2024 report, which noted over 4,000 therapies in development globally.

Simultaneously, the complexity of manufacturing advanced therapies is driving a strategic shift toward end-to-end integrated outsourcing models. Innovators encounter significant technical difficulties in scaling viral vector production and autologous cell processing, leading them to seek partners capable of providing a single-source solution from early-phase development through to commercialization. This comprehensive approach minimizes the logistical and regulatory risks associated with transferring technology between multiple vendors. In line with this trend, leading providers are investing heavily in integrated facilities; for example, Fujifilm Diosynth Biotechnologies committed an additional USD 1.2 billion in April 2024 to expand its large-scale cell culture facility, aiming to establish one of North America's largest end-to-end biopharmaceutical manufacturing sites.

Market Challenge

The scarcity of manufacturing slot capacity, coupled with a lack of highly skilled personnel, acts as a significant barrier to the growth of the Advanced Therapy Medicinal Products CDMO market. These constraints restrict the operational throughput of service providers, preventing them from fully absorbing the demand generated by biopharmaceutical innovators. Because these therapies require precise handling by experienced staff, Contract Development and Manufacturing Organizations are unable to rapidly scale their operations to meet client needs, which results in project backlogs and extended lead times for both clinical and commercial production.

This bottleneck directly impacts market revenue growth by causing delays in project initiation and milestone completion. The gap between the high demand for development services and the limited supply of technical resources effectively creates a ceiling on market performance. According to the Alliance for Regenerative Medicine, there were over 1,900 active clinical trials globally in the regenerative medicine sector in 2024. This substantial volume of pipeline activity intensifies the competition for limited manufacturing slots, ensuring that capacity constraints remain a primary factor slowing the overall trajectory of the outsourcing sector.

Market Trends

The expansion of CDMO operations into Asia-Pacific hubs is reshaping the global supply chain as service providers build large-scale manufacturing clusters in the region to take advantage of skilled labor and government incentives. This geographical diversification addresses the industry's need for redundant capacity and lessens reliance on Western-centric production, particularly for commercial-scale biologic and advanced therapy manufacturing. Companies are aggressively constructing mega-plants in locations such as Singapore and South Korea to serve global clients with competitive timelines and costs. For instance, WuXi Biologics announced in July 2025 the development of a 30,000-square-meter modular drug product facility at Tuas Biomedical Park in Singapore, designed to enhance its global manufacturing network.

concurrently, the market is shifting from transactional to strategic long-term partnerships, driven by the biopharmaceutical industry's need for guaranteed slot availability and supply chain security. Unlike traditional project-by-project outsourcing, these extended collaborations involve multi-year capacity reservations and dedicated production lines, effectively treating the CDMO as an extension of the client's internal network. This model provides financial stability for manufacturers while ensuring innovators have immediate access to resources during critical phases. According to Oxford Biomedica's interim results from September 2025, the company reported a contracted value of client orders totaling £149 million signed during the first half of the year, representing a 166 percent increase compared to the same period in 2024.

Key Market Players

Celonic AG
Rentschler Biopharma SE
Catalent, Inc.
Lonza Group AG
WuXi Advanced Therapies
Minaris Regenerative Medicine, LLC
Pluri Biotech Ltd.
REPROCELL USA Inc.
BioPhorum Operations Group
Cellares Corporation

Report Scope

In this report, the Global Advanced Therapy Medicinal Products CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advanced Therapy Medicinal Products CDMO Market, By Product

Gene Therapy
Cell Therapy
Tissue Engineered
Others

Advanced Therapy Medicinal Products CDMO Market, By Phase

Phase I
Phase II
Phase III
Phase IV

Advanced Therapy Medicinal Products CDMO Market, By Indication

Oncology
Cardiology
Central Nervous System
Musculoskeletal
Infectious disease
Immunology & inflammation
Others

Advanced Therapy Medicinal Products CDMO Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Advanced Therapy Medicinal Products CDMO Market.

Available Customizations:

Global Advanced Therapy Medicinal Products CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Advanced Therapy Medicinal Products CDMO Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
- 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
- 5.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Advanced Therapy Medicinal Products CDMO Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Phase
- 6.2.3. By Indication
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Advanced Therapy Medicinal Products CDMO Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Phase
    - 6.3.1.2.3. By Indication
- 6.3.2. Canada Advanced Therapy Medicinal Products CDMO Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Phase
    - 6.3.2.2.3. By Indication
- 6.3.3. Mexico Advanced Therapy Medicinal Products CDMO Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Phase
    - 6.3.3.2.3. By Indication

7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Phase
- 7.2.3. By Indication
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Phase
    - 7.3.1.2.3. By Indication
- 7.3.2. France Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Phase
    - 7.3.2.2.3. By Indication
- 7.3.3. United Kingdom Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Phase
    - 7.3.3.2.3. By Indication
- 7.3.4. Italy Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Phase
    - 7.3.4.2.3. By Indication
- 7.3.5. Spain Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Phase
    - 7.3.5.2.3. By Indication

8. Asia Pacific Advanced Therapy Medicinal Products CDMO Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Phase
- 8.2.3. By Indication
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Phase
    - 8.3.1.2.3. By Indication
- 8.3.2. India Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Phase
    - 8.3.2.2.3. By Indication
- 8.3.3. Japan Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Phase
    - 8.3.3.2.3. By Indication
- 8.3.4. South Korea Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Phase
    - 8.3.4.2.3. By Indication
- 8.3.5. Australia Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Phase
    - 8.3.5.2.3. By Indication

9. Middle East & Africa Advanced Therapy Medicinal Products CDMO Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Phase
- 9.2.3. By Indication
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Phase
    - 9.3.1.2.3. By Indication
- 9.3.2. UAE Advanced Therapy Medicinal Products CDMO Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Phase
    - 9.3.2.2.3. By Indication
- 9.3.3. South Africa Advanced Therapy Medicinal Products CDMO Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Phase
    - 9.3.3.2.3. By Indication

10. South America Advanced Therapy Medicinal Products CDMO Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Phase
- 10.2.3. By Indication
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Advanced Therapy Medicinal Products CDMO Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Phase
    - 10.3.1.2.3. By Indication
- 10.3.2. Colombia Advanced Therapy Medicinal Products CDMO Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Phase
    - 10.3.2.2.3. By Indication
- 10.3.3. Argentina Advanced Therapy Medicinal Products CDMO Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Phase
    - 10.3.3.2.3. By Indication

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Advanced Therapy Medicinal Products CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Celonic AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Rentschler Biopharma SE
15.3. Catalent, Inc.
15.4. Lonza Group AG
15.5. WuXi Advanced Therapies
15.6. Minaris Regenerative Medicine, LLC
15.7. Pluri Biotech Ltd.
15.8. REPROCELL USA Inc.
15.9. BioPhorum Operations Group
15.10. Cellares Corporation

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION